期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 43, 期 8, 页码 686-700出版社
CELL PRESS
DOI: 10.1016/j.tips.2022.04.002
关键词
-
资金
- National Institutes of Health (NIH) [R00 CA240896]
- Cancer Research Foundation Young Investigator Award
- Lynn Sage Scholar Award
- American Cancer Society [IRG-21-144-27]
- Bill Bass Foundation
- Northwestern University start-up funds
- Robert H. Lurie Comprehensive Cancer Center
- Department of Defense (DoD) Career Development [W81XWH-21-1-0380]
Glioblastoma (GBM) is a common and lethal brain tumor, and the symbiotic interaction between immune cells and GBM cells plays a critical role in tumor progression and therapy resistance. Targeting the tumor-immune symbiosis pharmacologically has emerged as a promising strategy for GBM treatment.
Glioblastoma (GBM) is the most common and highly lethal form of primary brain tumor in adults. The median survival of GBM patients is approximately 14-16 months despite multimodal therapies. Emerging evidence has substantiated the critical role of symbiotic interactions between GBM cells and noncancerous immune cells (e.g., myeloid cells and T cells) in regulating tumor progression and therapy resistance. Approaches to target the tumor-immune symbiosis have emerged as a promising therapeutic strategy for GBM. Here, we review the recent developments for pharmacological targeting of the GBM-immune symbiosis and highlight the role of such strategies to improve the effectiveness of immunothera-pies in GBM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据